Biocryst Pharmaceuticals Inc. (BCRX) intrinsic value & 10-year financials
Biocryst Pharmaceuticals Inc. (BCRX) has a Graham intrinsic value of $40.19 per share. At $7.79 on Oct 17, 2026, the stock trades 81% below that value. Over the last 10 fiscal years revenue grew 47.6% a year to $874.8M, with an average return on invested capital of -67.0%.
- Graham intrinsic value
- $40.19
- Share price (Oct 17, 2026)
- $7.79
- Price vs Graham value
- 81% below
- Market cap
- $1.7B
- Revenue (FY2025)
- $874.8M
- Revenue growth (10-yr CAGR)
- 47.6%
- ROIC (10-yr avg)
- -67.0%
- Free cash flow (FY2025)
- $344.9M
BCRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $874.8M | $263.9M | $1.21 | $344.9M | 39.0% | -148.0% |
| FY2024 | $450.7M | -$88.9M | -$0.43 | -$53.1M | -0.6% | 1.0% |
| FY2023 | $331.4M | -$226.5M | -$1.18 | -$97.3M | -31.3% | 33.8% |
| FY2022 | $270.8M | -$247.1M | -$1.33 | -$163.2M | -54.8% | 35.7% |
| FY2021 | $157.2M | -$184.1M | -$1.03 | -$144.5M | -113.1% | 58.9% |
| FY2020 | $17.8M | -$182.8M | -$1.09 | -$137.7M | -981.1% | 197.6% |
| FY2019 | $48.8M | -$108.9M | — | -$89.9M | -203.7% | -480.7% |
| FY2018 | $20.7M | -$101.3M | — | -$92.9M | -456.2% | -111.2% |
| FY2017 | $25.2M | -$65.8M | — | -$41.5M | -227.9% | -99.1% |
| FY2016 | $26.4M | -$55.1M | — | -$58.7M | -184.4% | -158.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOCRYST PHARMACEUTICALS INC is a consistent compounder, expanding top-line revenue at 47.6% annually over the past decade.
BIOCRYST PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -23.3% ROIC.
BIOCRYST PHARMACEUTICALS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOCRYST PHARMACEUTICALS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $40.19 per share.